Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

Recruiting now · Not applicable

Conditions studied: Lung Cancer (NSCLC)

In brief

This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.

Key facts

Study ID

NCT06849518

Run by

Ballad Health

People needed

30

Starts

2025-02-11

Expected to finish

2027-03-01

Last updated by the study team

2025-02-28

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients with a diagnosis of stage IV or inoperable stage IIIB NSCLC without planned primary radiation therapy undergoing anti-PD-1/L1 based ICI treatment.
• Chemo-immune or dual anti-PD-1/L1 with anti-CTLA-4 based regimens are eligible as long as receiving an anti-PD-1/L1 monoclonal antibody.
• A documented informed consent will be obtained prior to inclusion in the study. All discussions with patients will be held in strictest confidence and out of earshot of the general public. Patients will be fully informed that their participation in the study is voluntary. Patients may decline to be part of the study. Their decision to participate in the study will not affect the care they receive.

You may not qualify if…

• No anti-PD-1/L1 monoclonal antibody treatment.
• Planned primary radiation therapy.
• Small-cell lung cancer histology.

Where it is running

• Ballad Health Cancer Care — Kingsport, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.